These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 16707778)

  • 21. Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients.
    Fujikawa M; Togo T; Yoshimi A; Fujita J; Nomoto M; Kamijo A; Amagai T; Uchikado H; Katsuse O; Hosojima H; Sakura Y; Furusho R; Suda A; Yamaguchi T; Hori T; Kamada A; Kondo T; Ito M; Odawara T; Hirayasu Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):755-60. PubMed ID: 18226436
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adherence to Oral Antipsychotics Measured by Electronic Adherence Monitoring in Schizophrenia: A Systematic Review and Meta-analysis.
    Yaegashi H; Kirino S; Remington G; Misawa F; Takeuchi H
    CNS Drugs; 2020 Jun; 34(6):579-598. PubMed ID: 32219681
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The meaning of antipsychotic medication to patients with schizophrenia.
    Seeman MV; Seeman N
    J Psychiatr Pract; 2012 Sep; 18(5):338-48. PubMed ID: 22995961
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness.
    Velligan DI; Weiden PJ; Sajatovic M; Scott J; Carpenter D; Ross R; Docherty JP;
    J Clin Psychiatry; 2009; 70 Suppl 4():1-46; quiz 47-8. PubMed ID: 19686636
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Medication adherence studies in schizophrenia.
    Hamann J; Pitschel-Walz G; Kissling W
    Am J Psychiatry; 2004 Mar; 161(3):582; author reply 582-3. PubMed ID: 14992997
    [No Abstract]   [Full Text] [Related]  

  • 27. A peer support programme for enhancing adherence to oral antipsychotic medication in consumers with schizophrenia.
    Boardman G; McCann T; Kerr D
    J Adv Nurs; 2014 Oct; 70(10):2293-302. PubMed ID: 24628395
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Validity of electronically monitored medication adherence and conventional adherence measures in schizophrenia.
    Byerly MJ; Thompson A; Carmody T; Bugno R; Erwin T; Kashner M; Rush AJ
    Psychiatr Serv; 2007 Jun; 58(6):844-7. PubMed ID: 17535946
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antipsychotic treatment dosing profile in patients with schizophrenia evaluated with electronic monitoring (MEMS®).
    Acosta FJ; Ramallo-Fariña Y; Bosch E; Mayans T; Rodríguez CJ; Caravaca A
    Schizophr Res; 2013 May; 146(1-3):196-200. PubMed ID: 23474024
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Strategies for dosing and switching antipsychotics for optimal clinical management.
    Buckley PF; Correll CU
    J Clin Psychiatry; 2008; 69 Suppl 1():4-17. PubMed ID: 18484804
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of random-sequence riboflavin as a marker of medication compliance in chronic schizophrenics.
    Kapur S; Ganguli R; Ulrich R; Raghu U
    Schizophr Res; 1991 Dec; 6(1):49-53. PubMed ID: 1686184
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment adherence in schizophrenia and schizoaffective disorder.
    Goff DC; Hill M; Freudenreich O
    J Clin Psychiatry; 2011 Apr; 72(4):e13. PubMed ID: 21527119
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of patient and clinician perspectives in the assessment of antipsychotic medication adherence.
    Barbui C; Kikkert M; Mazzi MA; Becker T; Bindman J; Schene A; Nosè M; Helm H; Thornicroft G; Tansella M
    Psychopathology; 2009; 42(5):311-7. PubMed ID: 19672133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reasons for adherence and nonadherence: a pilot study comparing first- and multi-episode schizophrenia patients.
    Sapra M; Weiden PJ; Schooler NR; Sunakawa-McMillan A; Uzenoff S; Burkholder P
    Clin Schizophr Relat Psychoses; 2014 Jan; 7(4):199-206. PubMed ID: 23428784
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effects of interventions to improve compliance with antipsychotic medication in people suffering from schizophrenia-results of recent reviews].
    Puschner B; Born A; Giessler A; Helm H; Becker T; Angermeyer MC
    Psychiatr Prax; 2005 Mar; 32(2):62-7. PubMed ID: 15712037
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Subjective side effects of antipsychotics and medication adherence in people with schizophrenia.
    McCann TV; Clark E; Lu S
    J Adv Nurs; 2009 Mar; 65(3):534-43. PubMed ID: 19222651
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Review of treatments that can ameliorate nonadherence in patients with schizophrenia.
    Kane JM
    J Clin Psychiatry; 2006; 67 Suppl 5():9-14. PubMed ID: 16822091
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Understanding and addressing adherence issues in schizophrenia: from theory to practice.
    Weiden PJ
    J Clin Psychiatry; 2007; 68 Suppl 14():14-9. PubMed ID: 18284273
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Electronically monitored adherence in outpatients with schizophrenia or schizoaffective disorder: a comparison of first- vs. second-generation antipsychotics.
    Nakonezny PA; Byerly MJ
    Schizophr Res; 2006 Feb; 82(1):107-14. PubMed ID: 16376522
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States.
    Sun SX; Liu GG; Christensen DB; Fu AZ
    Curr Med Res Opin; 2007 Oct; 23(10):2305-12. PubMed ID: 17697454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.